Relixosan®

Suntegrilin
Usage:
  • Relief of musculoskeletal pain.
  • Alleviation of muscle blockage and spasms.
  • Reduction of neck, back, and shoulder pain.
  • Pharmaceutical form: 10 ml Injection Vial – 20 mg/10 ml
  • Generic name: Eptifibatide
  • Ingredients: 20 mg Eptifibatide
  • How to use: Intravenous (IV) Injection

Relixosan® is a topical gel with soothing and muscle-relaxing effects. It contains potent herbal ingredients, including Camphor, Menthol, and relaxing extracts. This product helps reduce muscle pain, bruising, fatigue, stiffness, and inflammation by increasing local blood flow and creating a cooling sensation.

Designed for fast absorption and excellent local effect. It is suitable for daily use by athletes, individuals with chronic pain, or those suffering from muscle tension and cramps.

Suntegrilin prevents platelet aggregation by inhibiting the GP IIb/IIIa receptor on the surface of platelets, thereby blocking fibrinogen binding. Clinical Results:

  • Reduction of thrombus (clot) formation in vessels.
  • Prevention of arterial re-occlusion following angioplasty.
  • Lowering the risk of heart attack in high-risk patients.
  • Rapid onset of action, specifically designed for emergency cardiac conditions.
  • Store at 2 to 8°C
  • Avoid freezing of the drug
  • The solution should be clear and free of particles before use
  • Use only in a hospital setting
  • Risk of bleeding exists; must be used with caution in patients with bleeding risks.

  • Interaction with anticoagulants such as Warfarin or Heparin.

  • Requires special attention in cases of:

    • Uncontrolled hypertension.

    • History of internal bleeding.

    • Active bleeding.

    • Recent surgery.

  • Should only be used during pregnancy and lactation under a physician’s discretion.

Contraindications:

  • Active bleeding or internal hemorrhage.

  • History of stroke within the last 30 days.

  • Malignant hypertension.

  • Severe renal failure.

  • Hypersensitivity to Eptifibatide or any drug components.

  • Common: Bleeding (nose, gums, injection site), decreased platelet count, nausea, headache, hypotension.

  • Less Common but Serious: Severe internal bleeding, major hematoma, allergic reactions, cardiac arrhythmias.

  • Note: The patient must be continuously monitored during injection.

Suntegrilin is supplied in standard hospital boxes containing one 20 mg/10 ml injection vial. The packaging is designed to protect the medication from light, impact, and contamination. Product information including drug name, composition, dosage, batch number, expiration date, and administration instructions is accurately and legibly printed on the box. This product is intended for hospital injection and is produced according to pharmaceutical quality and safety standards.

Reviews

There are no reviews yet.

Be the first to review “Relixosan®”

Your email address will not be published. Required fields are marked *

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

Product categories

Classification of major products of Biosun Pharmed Company

Products